GRACELL BIOTECHNOLOGIES-ADR (GRCL) Stock Price & Overview
NASDAQ:GRCL • US38406L1035
Current stock price
The current stock price of GRCL is 10.25 USD. Today GRCL is up by 0.05%. In the past month the price increased by 1.59%. In the past year, price increased by 412.5%.
GRCL Key Statistics
- Market Cap
- 989.867M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.18
- Dividend Yield
- N/A
GRCL Stock Performance
GRCL Stock Chart
GRCL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GRCL. When comparing the yearly performance of all stocks, GRCL is one of the better performing stocks in the market, outperforming 99.35% of all stocks.
GRCL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRCL. While GRCL seems to be doing ok healthwise, there are quite some concerns on its profitability.
GRCL Earnings
GRCL Forecast & Estimates
15 analysts have analysed GRCL and the average price target is 10.76 USD. This implies a price increase of 4.99% is expected in the next year compared to the current price of 10.25.
GRCL Groups
Sector & Classification
GRCL Financial Highlights
Over the last trailing twelve months GRCL reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.64% | ||
| ROE | -52.9% | ||
| Debt/Equity | 0.12 |
GRCL Ownership
GRCL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.95 | 364.65B | ||
| AMGN | AMGEN INC | 15.33 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.55 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.79 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.21 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.35 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.57 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.26 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRCL
Company Profile
Gracell Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 314 full-time employees. The company went IPO on 2021-01-08. The firm is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The firm is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
Company Info
IPO: 2021-01-08
GRACELL BIOTECHNOLOGIES-ADR
Building 3, 418 Guilin Road, Xuhui District
Shanghai SHANGHAI 215123 CN
CEO: William Wei Cao
Employees: 314
Phone: 862164031522
GRACELL BIOTECHNOLOGIES-ADR / GRCL FAQ
What does GRACELL BIOTECHNOLOGIES-ADR do?
Gracell Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 314 full-time employees. The company went IPO on 2021-01-08. The firm is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The firm is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
What is the current price of GRCL stock?
The current stock price of GRCL is 10.25 USD. The price increased by 0.05% in the last trading session.
Does GRCL stock pay dividends?
GRCL does not pay a dividend.
What is the ChartMill rating of GRACELL BIOTECHNOLOGIES-ADR stock?
GRCL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of GRACELL BIOTECHNOLOGIES-ADR (GRCL) based on its PE ratio?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
What is the ownership structure of GRACELL BIOTECHNOLOGIES-ADR (GRCL)?
You can find the ownership structure of GRACELL BIOTECHNOLOGIES-ADR (GRCL) on the Ownership tab.